Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser imaging may uncover secret triggers of lung disease

NCT ID NCT07597187

Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study explores whether a technique called LIBS, which maps chemical elements in lung tissue, can help doctors identify possible environmental or workplace causes of chronic lung diseases. Researchers will analyze stored biopsy samples from 70 adult patients using LIBS and an AI tool. The goal is to see if this approach provides useful information beyond standard tests, without requiring any extra procedures for participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a new tool to identify environmental or workplace exposures that may be causing lung disease, leading to better prevention and legal recognition.
What could go wrong
This is an early observational study with only 70 patients. The technique may not provide clear or useful information for many cases, and it does not test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with chronic lung diseases, including interstitial lung diseases, pulmonary granulomatoses such as sarcoidosis, and pulmonary emphysema, for whom a lung biopsy sample obtained during routine care is available for LIBS and IFF analysis. Participants may be identified retrospectively or prospectively in participating French hospital centers. Only patients who have not objected to the use of their health data and biological samples for research will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient aged 18 years or older. * Diagnosis or documented clinical suspicion of chronic lung disease, including interstitial lung disease, pulmonary granulomatosis such as sarcoidosis, or pulmonary emphysema. * Availability of a lung tissue biopsy sample obtained during routine medical care and stored as a formalin-fixed paraffin-embedded sample. * Sufficient medical record information to document the clinical context, occupational or environmental exposure history, smoking status, imaging, pathology reports, and other relevant routine-care data. * No documented objection to the secondary use of health data and biological samples for this research. Exclusion Criteria: * Documented objection to participation in the study or to the secondary use of health data or biological samples for research. * Missing, unavailable, degraded, or technically unusable biopsy sample. * Insufficient medical record information to document the clinical context or exposure history. * Lung condition outside the scope of the study, such as isolated acute infection, isolated cardiac disease, or primary lung cancer. * Patient under legal protection when the applicable legal conditions for non-opposition cannot be fulfilled.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lung diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease lung disorder occupational lung disease pulmonary emphysema sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lung diseases Environmental exposure Interstitial lung diseases (ILD) Occupational exposure Occupational lung diseases Pulmonary emphysema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Grenoble Alpes

    RECRUITING

    Grenoble, France

  • Centre Hospitalier Régional Universitaire Nancy (CHRU)

    RECRUITING

    Nancy, France

  • centre Hospitalier Universitaire Rouen (CHU)

    RECRUITING

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.